Case of fulminant type 1 diabetes induced by the anti‐programmed death‐ligand 1 antibody, avelumab
Abstract With the expansive use of immune checkpoint inhibitors, the frequency of immune‐related adverse events, including autoimmune type 1 diabetes, has been exponentially increased. The anti‐programmed death‐ligand 1 antibody, avelumab, has recently been approved for metastatic Merkel cell carcin...
Main Authors: | Yui Shibayama, Hiraku Kameda, Shoichiro Ota, Kazuhisa Tsuchida, Kyu Yong Cho, Akinobu Nakamura, Hideaki Miyoshi, Tatsuya Atsumi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-09-01
|
Series: | Journal of Diabetes Investigation |
Subjects: | |
Online Access: | https://doi.org/10.1111/jdi.13022 |
Similar Items
-
Fulminant myocarditis as a primary manifestation of H1N1 infection: A first reported case from Serbia
by: Goran Davidović, et al.
Published: (2016-05-01) -
Fulminate retinopathy of prematurity - Clinical characteristics and laser outcome
by: Shah Parag, et al.
Published: (2005-01-01) -
Fulminant type 1 diabetes mellitus associated with Coxsackievirus type B1 infection during pregnancy: a case report
by: Takahiro Hayakawa, et al.
Published: (2019-06-01) -
Drug-induced hypersensitivity reaction: A case of simultaneous thyroiditis and fulminant type 1 diabetes
by: Michael Marchese, et al.
Published: (2017-04-01) -
Transition of blood glucose level in a patient with pregnancy‐associated fulminant type 1 diabetes mellitus
by: Takahiro Ichikawa, et al.
Published: (2021-05-01)